South Korea Radioimmunoassay Market Size, Share, and COVID-19 Impact Analysis, By Type (Enzyme-Linked Immunosorbent Assay, Radioimmunoassay, Fluorescent Immunoassay, Chemiluminescent Immunoassay, and Western Blot), By Technology (Automated Immunoassay, Point of Care Immunoassay, and Lateral Flow Assay), and South Korea Radioimmunoassay Market Insights, Industry Trend, Forecasts to 2035

South Korea Radioimmunoassay Market Insights Forecasts to 2035

• The South Korea Radioimmunoassay Market Size was estimated at USD 30.0 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.42% from 2025 to 2035
• The South Korea Radioimmunoassay Market Size is Expected to Reach USD 53.6 Million by 2035

According to a research report published by Spherical Insights & Consulting, the South Korea Radioimmunoassay Market is anticipated to reach USD 53.6 million by 2035, growing at a CAGR of 5.42% from 2025 to 2035. The market for radioimmunoassay has expanded steadily as such of advancements in diagnostic methods and a rise in the need for tailored treatment.

Market Overview

The market for radioimmunoassay (RIA) is based on the need for extremely sensitive diagnostic instruments to quantify concentrations of substances like hormones and antigens in biological fluids. RIA's accuracy, facilitated by radioisotopes, makes possible the detection of trace analytes essential for the diagnosis and monitoring of diseases such as cancer and endocrine disorders. Moreover, the increasing prevalence of chronic diseases, especially cancer, is driving the usage of RIA because of its utility in early detection, tumor marker follow-up, and tailored treatment regimens through the identification of biomarkers. RIA finds common usage in medical research, especially drug development and clinical studies, where precise measurement of biological markers is critical. The pharmaceutical and biotechnology industries are adopting RIA to improve research quality and effectiveness. Medical specialties like oncology, toxicology, and endocrinology are major beneficiaries of its usage due to the necessity for low-concentration substance precise quantification. In addition, government funding and support for research in oncology and infectious diseases are driving market growth. Also, the investments in technological innovations are likely to make RIA more cost-effective and efficient, further increasing its adoption. Overall, RIA continues to be an essential tool in clinical diagnostics and biomedical research, facilitating innovation and better patient outcomes.

Report Coverage

This research report categorizes the market for South Korea radioimmunoassay market based on various segments and regions forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea radioimmunoassay market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea radioimmunoassay market.

Driving Factors

The South Korea radioimmunoassay (RIA) market is driven by rising incidences of chronic diseases such as cancer and thyroid disorders, increasing demand for accurate diagnostic tools, and advancements in healthcare infrastructure. Growing awareness about early disease detection and the need for highly sensitive testing methods further drive the market growth. Additionally, support from government health programs and ongoing investments in biotechnology research and development contribute significantly to the expansion and innovation of RIA technologies across clinical and research settings.

Restraining Factors

There are several barriers to the growth of the South Korea radioimmunoassay (RIA) market. High operating expenses linked with specialized machinery, radioactive isotopes, and disposal costs raise the cost burden on healthcare providers and diagnostic centers. The use of highly regulated procedures for the handling of radioactive compounds also requires special training and certification, which raises costs and complexity.

Market Segmentation

The South Korea radioimmunoassay market share is classified into type and technology.

• The enzyme-linked immunosorbent assay segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea radioimmunoassay market is segmented by type into enzyme-linked immunosorbent assay, radioimmunoassay, fluorescent immunoassay, chemiluminescent immunoassay, and western blot. Among these, the enzyme-linked immunosorbent assay segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The enzyme-linked immunosorbent assay (ELISA) is a popular option for biomarker validation and serological testing because of its high specificity, adaptability, and potential for mass-screening applications.

• The automated immunoassay segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea radioimmunoassay market is segmented by technology into automated immunoassay, point-of-care immunoassay, and lateral flow assay. Among these, the automated immunoassay segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is because of the boosted throughput and efficiency by streamlining laboratory testing procedures; these systems are crucial for high-volume testing facilities, guaranteeing accurate results quickly.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea radioimmunoassay market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Beckman Coulter
• Abbott Laboratories
• Hologic
• DiaSorin
• Siemens Healthineers
• Thermo Fisher Scientific
• Randox Laboratories
• BioRad Laboratories
• Eiken Chemical
• Fujirebio
• Ortho Clinical Diagnostics
• American BioProducts
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea radioimmunoassay market based on the below-mentioned segments:

South Korea Radioimmunoassay Market, By Type

• Enzyme-Linked Immunosorbent Assay
•  Radioimmunoassay
•  Fluorescent Immunoassay
•  Chemiluminescent Immunoassay
•  Western Blot

South Korea Radioimmunoassay Market, By Technology

• Automated Immunoassay
• Point of Care Immunoassay
•  Lateral Flow Assay